2024
Use of Early Ketamine Sedation and Association With Clinical and Cost Outcomes Among Mechanically Ventilated Patients With COVID-19: A Retrospective Cohort Study
Royce-Nagel G, Jarzebowski M, Wongsripuemtet P, Krishnamoorthy V, Fuller M, Ohnuma T, Treggiari M, Yaport M, Cobert J, Garrigan E, Bartz R, Raghunathan K. Use of Early Ketamine Sedation and Association With Clinical and Cost Outcomes Among Mechanically Ventilated Patients With COVID-19: A Retrospective Cohort Study. Critical Care Explorations 2024, 6: e1105. PMID: 38904975, PMCID: PMC11196078, DOI: 10.1097/cce.0000000000001105.Peer-Reviewed Original ResearchConceptsRenal replacement therapyLength of stayHospital length of stayHigher hospital mortalityKetamine infusionTotal hospital costsHospital mortalityVasopressor daysKetamine useVentilator daysSample of U.S. hospitalsRenal replacement therapy useAssociated with higher hospital mortalityDays of mechanical ventilationAssociated with in-hospital mortalityHospital costsManagement of critically ill patientsExtracorporeal membrane oxygenationPropensity score matching analysisRetrospective cohort studyPremier Healthcare DatabaseDays of hospitalizationDays of intubationMechanically ventilated patientsCritically ill patients
2021
Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study
Zhao X, Gao C, Dai F, Treggiari MM, Deshpande R, Meng L. Treatments Associated with Lower Mortality among Critically Ill COVID-19 Patients: A Retrospective Cohort Study. Anesthesiology 2021, 135: 1076-1090. PMID: 34597362, DOI: 10.1097/aln.0000000000003999.Peer-Reviewed Original ResearchConceptsIll COVID-19 patientsCOVID-19 patientsPropensity score-matched analysisRetrospective cohort studyLower mortalityHospital mortalityCohort studyMultivariable analysisYale New Haven Health SystemIntensive care unit admissionOrgan support treatmentUse of apixabanCare unit admissionSevere COVID-19Intensive care unitCOVID-19 mortalityLower COVID-19 mortalityApixaban treatmentUnit admissionAspirin treatmentCare unitTreatment AssociatedCandidate treatmentSupport treatmentPatientsEarly but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
COVID-19 mortality risk for older men and women
Yanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health 2020, 20: 1742. PMID: 33213391, PMCID: PMC7675386, DOI: 10.1186/s12889-020-09826-8.Peer-Reviewed Original ResearchConceptsIncident rate ratiosCOVID-19 mortalityCOVID-19 mortality ratesMortality rateCOVID-19 deathsCOVID-19COVID-19 mortality riskPoisson mixed effects regression modelsHigh COVID-19 mortality ratesAge-specific ratesMixed effects regression modelsCOVID-19 casesAge 54Mortality riskHigh riskOlder menConsecutive weeksAge 65Age groupsSix-week periodYoung individualsRate ratioDeathEffects regression modelsWomen